Nivolumab +/- Ipilimumab Immunomonitoring in Metastatic Melanoma

Immune Modulation Study in Patients With Metastatic Melanoma Treated With a First Line Therapy of Nivolumab +/- Ipilimumab (IMMUNONIVO/MelpredictPD1).

This is an open bi-centric prospective non-randomized study in patients with metastatic melanoma treated with a first line treatment of Nivolumab +/- Ipilimumab. The aim of the study is to characterize the immune cells modulations under anti-PD-1 +/- anti-CTLA4 and identify the differences between responder and non-responder patients.

Inclusion Criteria:

• Men and women aged ≥ 18 years of age.
• Patient with metastatic or unresectable melanoma
• Nivolumab or Nivolumab + Ipilimumab treatment indication
• Skin biopsies available
• Patient affiliated to or a beneficiary of a social security category.
• Signed Written Informed Consent.
• Patient who agrees to the storage of his biological samples

Exclusion Criteria:

• Treated haematological malignancies Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications
• Patients with autoimmune disease.
• Ocular melanoma